The importance of FLT3 mutational analysis in acute myeloid leukemia
Published 2017 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
The importance of FLT3 mutational analysis in acute myeloid leukemia
Authors
Keywords
-
Journal
LEUKEMIA & LYMPHOMA
Volume -, Issue -, Pages 1-14
Publisher
Informa UK Limited
Online
2017-11-22
DOI
10.1080/10428194.2017.1399312
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Gilteritinib, a FLT3/AXL inhibitor, shows antileukemic activity in mouse models of FLT3 mutated acute myeloid leukemia
- (2017) Masamichi Mori et al. INVESTIGATIONAL NEW DRUGS
- Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1–2 study
- (2017) Alexander E Perl et al. LANCET ONCOLOGY
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation
- (2017) Richard M. Stone et al. NEW ENGLAND JOURNAL OF MEDICINE
- FLT3 Mutation Testing in Acute Myeloid Leukemia
- (2017) Arjun Gupta et al. JAMA Oncology
- Leukemogenic potency of the novel FLT3-N676K mutant
- (2016) Kezhi Huang et al. ANNALS OF HEMATOLOGY
- Allogeneic Stem Cell Transplantation Improves Survival in Patients with Acute Myeloid Leukemia Characterized by a High Allelic Ratio of Mutant FLT3-ITD
- (2016) Anthony D. Ho et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic Transplantation in First Remission Improves Outcomes Irrespective of FLT3 -ITD Allelic Ratio in FLT3 -ITD–Positive Acute Myelogenous Leukemia
- (2016) Betül Oran et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Allogeneic Hematopoietic Stem Cell Transplantation in FLT3 -ITD–Positive Acute Myelogenous Leukemia: The Role for FLT3 Tyrosine Kinase Inhibitors Post-Transplantation
- (2016) Gary J. Schiller et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- How I treat FLT3-mutated AML
- (2016) Keith W. Pratz et al. BLOOD
- Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies
- (2016) Thomas McKerrell et al. BLOOD
- Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel
- (2016) Hartmut Döhner et al. BLOOD
- Inhibition of FLT3 in AML: a focus on sorafenib
- (2016) A Antar et al. BONE MARROW TRANSPLANTATION
- Haematopoietic cell transplantation with and without sorafenib maintenance for patients withFLT3-ITD acute myeloid leukaemia in first complete remission
- (2016) Andrew M. Brunner et al. BRITISH JOURNAL OF HAEMATOLOGY
- Precision medicine in acute myeloid leukemia: Hope, hype or both?
- (2016) Vinay Prasad et al. LEUKEMIA RESEARCH
- Genomic Classification and Prognosis in Acute Myeloid Leukemia
- (2016) Elli Papaemmanuil et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improvement in clinical outcome ofFLT3ITD mutated acute myeloid leukemia patients over the last one and a half decade
- (2015) Talha Badar et al. AMERICAN JOURNAL OF HEMATOLOGY
- FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML
- (2015) Y Song et al. BONE MARROW TRANSPLANTATION
- Decitabine and Sorafenib Therapy in FLT-3 ITD-Mutant Acute Myeloid Leukemia
- (2015) Monica R. Muppidi et al. Clinical Lymphoma Myeloma & Leukemia
- Sorafenib Maintenance Appears Safe and Improves Clinical Outcomes in FLT3-ITD Acute Myeloid Leukemia After Allogeneic Hematopoietic Cell Transplantation
- (2015) Ahmad Antar et al. Clinical Lymphoma Myeloma & Leukemia
- The utility of next-generation sequencing in diagnosis and monitoring of acute myeloid leukemia and myelodysplastic syndromes
- (2015) E. J. Duncavage et al. International Journal of Laboratory Hematology
- Addition of sorafenib versus placebo to standard therapy in patients aged 60 years or younger with newly diagnosed acute myeloid leukaemia (SORAML): a multicentre, phase 2, randomised controlled trial
- (2015) Christoph Röllig et al. LANCET ONCOLOGY
- Rare FLT3 deletion mutants may provide additional treatment options to patients with AML: an approach to individualized medicine
- (2015) N Chatain et al. LEUKEMIA
- A Novel Tandem Duplication Assay to Detect Minimal Residual Disease in FLT3/ITD AML
- (2015) Ming-Tseh Lin et al. Molecular Diagnosis & Therapy
- Revealing very small FLT3 ITD mutated clones by ultra-deep sequencing analysis has important clinical implications in AML patients
- (2015) Elisa Zuffa et al. Oncotarget
- Minimal Residual Disease in Acute Myeloid Leukemia—Current Status and Future Perspectives
- (2015) Sabine Kayser et al. Current Hematologic Malignancy Reports
- Rates of complete diagnostic testing for patients with acute myeloid leukemia
- (2015) Tara L. Lin et al. Cancer Medicine
- Improved FLT3 Internal Tandem Duplication PCR Assay Predicts Outcome after Allogeneic Transplant for Acute Myeloid Leukemia
- (2014) Michael R. Grunwald et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Phase I Trial of Maintenance Sorafenib after Allogeneic Hematopoietic Stem Cell Transplantation for Fms-like Tyrosine Kinase 3 Internal Tandem Duplication Acute Myeloid Leukemia
- (2014) Yi-Bin Chen et al. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION
- Impact of FLT3ITD mutant allele level on relapse risk in intermediate-risk acute myeloid leukemia
- (2014) D. C. Linch et al. BLOOD
- Differential impact of allelic ratio and insertion site in FLT3-ITD-positive AML with respect to allogeneic transplantation
- (2014) R. F. Schlenk et al. BLOOD
- Resistance prediction in AML: analysis of 4601 patients from MRC/NCRI, HOVON/SAKK, SWOG and MD Anderson Cancer Center
- (2014) R B Walter et al. LEUKEMIA
- Comprehensive analysis of genetic alterations and their prognostic impacts in adult acute myeloid leukemia patients
- (2014) R Kihara et al. LEUKEMIA
- Exome sequencing identifies recurring FLT3 N676K mutations in core-binding factor leukemia
- (2013) S. Opatz et al. BLOOD
- Activity of ponatinib against clinically-relevant AC220-resistant kinase domain mutants of FLT3-ITD
- (2013) C. C. Smith et al. BLOOD
- Favorable outcome of patients with acute myeloid leukemia harboring a low-allelic burden FLT3-ITD mutation and concomitant NPM1 mutation: relevance to post-remission therapy
- (2013) M. Pratcorona et al. BLOOD
- Phase 2 study of azacytidine plus sorafenib in patients with acute myeloid leukemia and FLT-3 internal tandem duplication mutation
- (2013) F. Ravandi et al. BLOOD
- Sorafenib in Combination With Intensive Chemotherapy in Elderly Patients With Acute Myeloid Leukemia: Results From a Randomized, Placebo-Controlled Trial
- (2013) Hubert Serve et al. JOURNAL OF CLINICAL ONCOLOGY
- The importance of relative mutant level for evaluating impact on outcome of KIT, FLT3 and CBL mutations in core-binding factor acute myeloid leukemia
- (2013) C Allen et al. LEUKEMIA
- The secondary FLT3-ITD F691L mutation induces resistance to AC220 in FLT3-ITD+ AML but retains in vitro sensitivity to PKC412 and Sunitinib
- (2013) C Albers et al. LEUKEMIA
- Medium-sizedFLT3internal tandem duplications confer worse prognosis than short and long duplications in a non-elderly acute myeloid leukemia cohort
- (2013) Magdalena Koszarska et al. LEUKEMIA & LYMPHOMA
- Conservative management of early-stage epithelial ovarian cancer: results of a large retrospective series
- (2012) R. Fruscio et al. ANNALS OF ONCOLOGY
- The FLT3ITD mRNA level has a high prognostic impact in NPM1 mutated, but not in NPM1 unmutated, AML with a normal karyotype
- (2012) F. Schneider et al. BLOOD
- A novel hierarchical prognostic model of AML solely based on molecular mutations
- (2012) V. Grossmann et al. BLOOD
- Influence of FLT3-internal tandem duplication allele burden and white blood cell count on the outcome in patients with intermediate-risk karyotype acute myeloid leukemia
- (2012) Jonathan How et al. CANCER
- Impact of FLT3 Internal Tandem Duplication on the Outcome of Related and Unrelated Hematopoietic Transplantation for Adult Acute Myeloid Leukemia in First Remission: A Retrospective Analysis
- (2012) Salut Brunet et al. JOURNAL OF CLINICAL ONCOLOGY
- Detection of FLT3 Internal Tandem Duplication in Targeted, Short-Read-Length, Next-Generation Sequencing Data
- (2012) David H. Spencer et al. JOURNAL OF MOLECULAR DIAGNOSTICS
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemia
- (2012) Catherine C. Smith et al. NATURE
- Prognostic Relevance of Integrated Genetic Profiling in Acute Myeloid Leukemia
- (2012) Jay P. Patel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Application of next-generation sequencing in clinical oncology to advance personalized treatment of cancer
- (2012) Yan-Fang Guan et al. Chinese Journal of Cancer
- Phase IIB Trial of Oral Midostaurin (PKC412), the FMS-Like Tyrosine Kinase 3 Receptor (FLT3) and Multi-Targeted Kinase Inhibitor, in Patients With Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome With Either Wild-Type or Mutated FLT3
- (2010) Thomas Fischer et al. JOURNAL OF CLINICAL ONCOLOGY
- Insertion of FLT3 internal tandem duplication in the tyrosine kinase domain-1 is associated with resistance to chemotherapy and inferior outcome
- (2009) S. Kayser et al. BLOOD
- AC220 is a uniquely potent and selective inhibitor of FLT3 for the treatment of acute myeloid leukemia (AML)
- (2009) P. P. Zarrinkar et al. BLOOD
- Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet
- (2009) H. Dohner et al. BLOOD
- FMS-Like Tyrosine Kinase 3-Internal Tandem Duplication Tyrosine Kinase Inhibitors Display a Nonoverlapping Profile of Resistance Mutations In vitro
- (2009) N. von Bubnoff et al. CANCER RESEARCH
- Mutant FLT3: A Direct Target of Sorafenib in Acute Myelogenous Leukemia
- (2008) Weiguo Zhang et al. JNCI-Journal of the National Cancer Institute
- Mutations and Treatment Outcome in Cytogenetically Normal Acute Myeloid Leukemia
- (2008) Richard F. Schlenk et al. NEW ENGLAND JOURNAL OF MEDICINE
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowBecome a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get Started